Speaker(s): 

Matthew Nelson, DO; Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Dyan Cawley, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• define indications for FH screening
• evaluate patients to lipid specialists appropriately
• order genetic testing for FH when indicated
• utilize electronic health record resources effectively to facilitate aspects of FH care and management

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Michael Lesko, DO, Activity Director, Samuel Gidding, MD, David Rolston, MD, Marie Kobylinski, MD, Matthew Nelson, DO, Shuping Ge, MD, Caroline deRichemond, CRNP, Elizabeth Bordy, PA-C,  Timothy Shuey, DO and Tyler Schubert have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Laney Jones, PharmD, has disclosed a relevant financial relationship with Amgen. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commerical Support for this Session

None.